Subscribe for unlimited access to DynaMed content, CME/CE & MOC credit, and email alerts on content you follow.

Already subscribed? Sign in now

Learn more about CME

Management of Systemic Lupus Erythematosus (SLE)

MoreVert
AddCircleOutlineFollow
ShareShare
AddCircleOutlineFollow
Follow
ShareShare
Share

You must be a subscriber to see the full topic content.

  • KeyboardArrowRight

    Overview and Recommendations

    • Background

    • Evaluation

    • Management

    • Disease Activity Monitoring and Follow-up

  • Related Summaries

  • Definitions

  • KeyboardArrowRight

    Considerations before Initiating Treatment

    • General considerations

    • Screening and baseline testing prior to treatment initiation

  • KeyboardArrowRight

    Approach to Management

    • Treat-to-target

    • European League Against Rheumatism (EULAR) 2019 recommendations for the management of SLE

    • Neuropsychiatric SLE (NPSLE)

    • Lupus nephritis (LN)

    • Cutaneous lupus erythematosus (CLE)

    • Management of SLE during pregnancy

    • Management of antiphospholipid antibodies in SLE

  • Disease Activity Indices and Outcome Measures

  • KeyboardArrowRight

    Medications

    • Antimalarials

    • KeyboardArrowRight

      Glucocorticoids

      • General information

      • Efficacy

      • Safety and adverse events

    • Nonsteroidal anti-inflammatory drugs (NSAIDs)

    • Immunosuppressive agents

    • KeyboardArrowRight

      Biologics and small molecules

      • European League Against Rheumatism (EULAR) recommendations on use of biologics for management of SLE

      • Belimumab

      • Rituximab

      • Other biologics under investigation

    • Androgenic therapy

    • Other medications

  • Stem Cell Transplantation

  • KeyboardArrowRight

    Adjunct and Nonpharmacologic Therapy

    • Diet

    • Activity

    • Counseling

    • Other therapies

  • Other Considerations for Medication Use in Patients with SLE

  • Immunizations

  • KeyboardArrowRight

    Follow-up

    • Recommendations on laboratory testing and other monitoring

    • Monitoring for drug toxicity

    • Monitoring for comorbidities

  • KeyboardArrowRight

    Guidelines and Resources

    • KeyboardArrowRight

      Guidelines

      • International guidelines

      • United States guidelines

      • United Kingdom guidelines

      • Canadian guidelines

      • European guidelines

      • Asian guidelines

      • Central and South American guidelines

    • Review articles

    • MEDLINE search

  • Patient Information

  • KeyboardArrowRight

    ICD Codes

    • ICD-10 codes

  • KeyboardArrowRight

    References

    • General references used

    • Recommendation grading systems used

    • Synthesized Recommendation Grading System for DynaMed

    • DynaMed Editorial Process

    • Special acknowledgements

    • How to cite

Topic Editor
Jefferson R. Roberts MD
KeyboardArrowDown
Affiliations

Assistant Clinical Professor, University of Hawaii, John A. Burns School of Medicine; Hawaii, United States; Chief of Rheumatology Service and Chief of Medical Simulation, Tripler Army Medical Center; Hawaii, United States

Conflicts of Interest

Dr. Roberts declares no relevant financial conflicts of interest.

Recommendations Editor
Esther Jolanda van Zuuren MD
KeyboardArrowDown
Affiliations

Head of Allergy, Dermatology, and Venereology, Leiden University Medical Centre; Netherlands

Conflicts of Interest

Dr. van Zuuren declares no relevant financial conflicts of interest.

Deputy Editor
Vito Iacoviello MD, FIDSA
KeyboardArrowDown
Affiliations

Deputy Editor of Infectious Diseases, Immunology and Rheumatology, Dynamed; Massachusetts, United States; Assistant Professor of Medicine, Harvard Medical School; Massachusetts, United States; Chief of the Division of Infectious Diseases, Mount Auburn Hospital; Massachusetts, United States

Conflicts of Interest

Dr. Iacoviello declares no relevant financial conflicts of interest.

CheckCircle

top